Retrophin (RTRX) Tops Q2 EPS by 25c, Beats on Revenues

Retrophin (NASDAQ: RTRX) reported Q2 EPS of $0.03, $0.25 better than the analyst estimate of ($0.22). Revenue for the quarter came in at $39 million versus the consensus estimate of $37.36 million.

• Dosed the first patient in the Phase 3 FORT (FOsmetpantotenate Replacement Therapy) Study of fosmetpantotenate (RE-024) in pantothenate kinase-associated neurodegeneration (PKAN)
• Protocol design for Phase 3 trial of sparsentan in focal segmental glomerulosclerosis (FSGS) is complete and preparation for submission of the protocol to the U.S. Food and Drug Administration (FDA) is underway
• Recent expansion of sparsentan intellectual property estate expected to extend U.S. and European exclusivity for treating glomerulosclerosis, including FSGS, until at least 2030
• Net product sales for the second quarter of 2017 were $38.8 million, compared to $33.3 million for the same period in 2016
• Cash, cash equivalents and marketable securities, as of June 30, 2017, totaled $296.0 million

For earnings history and earnings-related data on Retrophin (RTRX) click here.

You May Also Be Interested In

• Toll Brothers (TOL) Tops Q3 EPS by 5c, reaffirms guidance
• Flexsteel (FLXS) Tops Q4 EPS by 24c, Beats on Revenue; Offers Q1 Revenue Guidance
• La-Z-Boy (LZB) Misses Q1 EPS by 6c, Misses on Revenue; Offers Weak Q2 Revenue Guidance